Sebastian, FL -- Long time pharmaceutical industry veteran Pat Earl has joined XStream Systems, Inc., as the Vice President, Business Development.

"Pat's role as Vice President Business Development at XStream will be focused on implementing Pharmaceutical Supply Chain strategies to increase market penetration of the XT250TM Materials Identification Systems with pharmaceutical distributors, drug wholesalers, manufacturers and reverse distributors. Her experience and past success in pharmaceutical distribution industry is a perfect fit for XStream," stated Alan Clock, Senior Vice President at XStream Systems.

Earl has been actively involved in the pharmaceutical wholesale distribution industry since joining Meyers and Company, a predecessor of AmerisourceBergen Drug Company, in 1986. She has held a variety of management positions at AmerisourceBergen including Vice President/General Manager of their Toledo, Ohio Division and Corporate Vice President of Strategic Development for Health Systems and Alternative Care. She developed and implemented the hospital and alternative care segment's strategic initiatives.
Earl played a significant role in the strategic positioning of the drug company's technology and service offerings that enhanced patient safety at dispensing and bedside, as well as increased operational efficiencies that provided cost savings to the health systems and alternative care providers.

Most recently, she was the Vice President of Drug Divisions and Vice President of Institutional Marketing at H.D. Smith. She has served on a number of HDMA and industry groups that focused on improving medication safety at the wholesale distribution level through eliminating unsafe practices in the supply chain.

Ensuring a Safe Drug Supply Chain

XStream Systems, Inc. has a unique and innovative solution to eliminate the record number of counterfeit and adulterated pharmaceutical products entering the worldwide marketplace. The trend of counterfeit pharmaceuticals is problematic and represents a major National Security risk in the United States. The Prescription Drug Marketing Act of 1987 (PDMA) was enacted (1) to ensure that drugs purchased by consumers are safe and effective, and (2) to avoid the unacceptable risk to American consumers from counterfeit, adulterated, misbranded, sub-potent or expired drugs. The legislation was necessary to increase safeguards in the drug distribution process and to prevent the introduction and retail sale of substandard, ineffective or counterfeit drugs. Recently XStream Systems, Inc. has seen that the Federal and State regulatory agencies have established various Pedigree requirements in an attempt to address these critical issues. However, the Pedigree requirements do not include authentication and validation of the actual drugs. It is believed that the number of counterfeit and contaminated drugs will continue to increase unless effective countermeasures can be deployed. The most definitive way to effectively protect U.S. consumers is by verifying a drug's efficacy at each 'transfer point' along the U.S. Supply Chain.

XStream Systems, Inc. offers unique patented systems based on Energy-Dispersive X-Ray Diffraction (EDXRD), a highly sophisticated and accurate technology that can detect counterfeit, adulterated or mis-labeled pharmaceuticals. For more information contact Roger Sobkowiak.

More Voices